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Abstract
Carbonic anhydrase IX (CAIX, gene G250/MN-encoded transmembrane protein) is highly expressed in various human
epithelial tumors such as renal clear cell carcinoma (RCC), but absent from the corresponding normal tissues. Besides the CA
signal transduction activity, CAIX may serve as a biomarker in early stages of oncogenesis and also as a reliable marker of
hypoxia, which is associated with tumor resistance to chemotherapy and radiotherapy. Although results from preclinical
and clinical studies have shown CAIX as a promising target for detection and therapy for RCC, only a limited number of
murine monoclonal antibodies (mAbs) and one humanized mAb are available for clinical testing and development. In this
study, paramagnetic proteoliposomes of CAIX (CAIX-PMPLs) were constructed and used for anti-CAIX antibody selection
from our 27 billion human single-chain antibody (scFv) phage display libraries. A panel of thirteen human scFvs that
specifically recognize CAIX expressed on cell surface was identified, epitope mapped primarily to the CA domain, and
affinity-binding constants (KD) determined. These human anti-CAIX mAbs are diverse in their functions including induction
of surface CAIX internalization into endosomes and inhibition of the carbonic anhydrase activity, the latter being a unique
feature that has not been previously reported for anti-CAIX antibodies. These human anti-CAIX antibodies are important
reagents for development of new immunotherapies and diagnostic tools for RCC treatment as well as extending our
knowledge on the basic structure-function relationships of the CAIX molecule.
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Introduction
Renal cell carcinoma (RCC) accounts for ,3% of all adult
malignancies. Each year in the Unites States there are .30,000
newly diagnosed cases and more than 10,000 deaths [1–3]. RCC
is resistant to virtually all conventional modes of treatment, such as
radiotherapy and chemotherapy [2,4–6], reinforcing the urgent
need for developing new therapeutic strategies. RCC is a
clinicopathologically heterogeneous disease, traditionally subdivid-
ed into clear cell, granular cell, papillary, chromophobe, spindle
cell, cystic, and collecting duct carcinoma subtypes based on
morphological features according to the WHO International
Histological Classification of Kidney Tumors [7] with clear cell
RCC as the most common adult renal neoplasm, representing
70% of all renal neoplasm. RCC is one of the few tumors where
spontaneous regression of metastatic disease has been documented
after tumor nephrectomy, treatment with placebo in phase III
trials or after inflammatory or infectious events [8,9]. These
observations have provided strong evidence of the importance of
the immune system in the control of this cancer. Therefore, much
attention has been focused on immunotherapeutic modalities for
the treatment of RCC.
Important prerequisites for a successful immunotherapy include
(a) identification of tumor-associated surface antigens that are not
expressed in normal tissues, and (b) discovery of highly specific
antibodies to such antigens. The carbonic anhydrase IX (CAIX)
is one of the most studied surface antigens in RCC. The gene
for CAIX is located on chromosomes 9p12 to 13 and encodes
a transmembrane protein that binds zinc and has CA activity
[10–12]. It is N-glycosylated, and forms oligomers in the non-
reduced state [13,14]. Sequence analysis of the predicted CAIX
protein shows that it contains a signal peptide (aa 1–37), an
extracellular domain (ECD, aa 38–414) that consists of a carbonic
anhydrase region located close to the plasma membrane (CA, aa
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domain (PG, aa 53–111) named after its significant homology
(38% identity) with a keratin sulfate attachment domain of a
human large aggregating proteoglycan, aggrecan [15], a hydro-
phobic transmembrane region of 20 amino acids (aa 415–434) and
a small C-terminus cytoplasmic portion of 25 amino acids (aa 435–
459). While CAIX appears at malignant transformation and stains
positive in about 95% of clear cell RCC specimens as well as in
most renal cell metastases, no CAIX was detected on the surface of
normal adult or fetal tissues except its cytoplasmic expression in
the epithelium of the bile ducts and small intestine together with
the mucous cells of the gastric epithelium [16]. This restricted
surface expression of CAIX makes it an excellent target for RCC
immunotherapy.
The functional significance of CAIX expression in tumorigenesis
remainsunclear.CAIXexpressioncaninducemalignantphenotype
in murine NIH 3T3 fibroblasts, suggesting that CAIX may play a
role in control of cell proliferation and transformation [10]. Possible
relevance of CAIX to the regulation of cell interactions and
proliferation in RCC oncogenesis has been suggested by its cell
density-regulated expression and association with tumors [17,18].
CAIX expression has been shown to modulate E-cadherin-
mediated cell adhesion via interaction with b-catenin [19]. Such
destabilization of E-cadherin-caterin interactions results in reduced
cell adhesion that is associated with tumorigenesis and invasion
[20,21]. In Von Hippel-Landau (VHL) gene-defective tumors,
CAIX is overexpressed [22] and may contribute to the tumor
microenvironment by maintaining extracellular acidic pH and
helping cancer cells grow and metastasize [23,24].
To date, two mAbs against human CAIX have been extensively
studied. In 1986, Oosterwijk and colleagues reported the isolation
of a murine IgG1 mAb termed G250, which preferentially
recognized a surface antigen that was associated with 46 of 47
primary RCC and 7 of 8 RCC metastases while no staining
observed in normal kidney tissues [16]. In 1992, Pastorekova ´ and
colleagues reported on a murine IgG2b mAb termed M75 with
similar properties (13). The antigen recognized by G250 and M75
was cloned, found to be identical, and named CAIX/MN/G250
[10,12]. The M75 epitope has been localized to the PG domain of
CAIX [25]. In order to avoid the human anti-mouse antibody
(HAMA) responses seen with antibodies of murine origin, a
chimeric form of G250 (mouse Fv and human IgG1 Fc) termed
cG250 or WX-G250 was developed [26] and tested for its safety
and tolerance in several clinical trials. The results showed that the
cG250 was well tolerated and safe with certain clinical benefits
such as disease stabilization [27–30] and increased median survival
rates (www.wilex.com). As the level of CAIX expression has been
shown to correlate with patient’s prognosis, survival, and response
to IL-2 therapy [31,32], anti-CAIX mAbs G250 and M75 also
have great promise as diagnostic/prognostic tools that could aid
with treatment decisions [31,33–36].
Although with significant diagnostic and therapeutic potential
for RCC, only a limited number of mouse anti-human CAIX
antibodies have been identified [13,16,37] and essentially only one
humanized anti-CAIX mAb has been evaluated in the clinical
setting. As such, an interesting but to our knowledge unanswered
question is whether antibodies to other epitopes of the CAIX
would be more effective in recruiting effecter cells or able to
antagonize any effect on cell proliferation and transformation that
may be mediated through CAIX. In an effort to develop effective
therapeutic reagents for RCC, a panel of high affinity human
monoclonal antibodies against CAIX was selected from our 27
billion-member human scFv-phage display library. These anti-
bodies were extensively evaluated by measurement of affinity
binding constants, epitope mapping, inhibition of the CA
enzymatic activity and capacity to induce CAIX internalization.
Methods
Cell Culture
Human renal clear cell carcinoma (RCC) cell line sk-rc-52
(CAIX positive) and sk-rc-59 (CAIX negative) were obtained from
Dr. Gerd Ritter (Memorial Sloan-Kettering Cancer Center, New
York, NY). These lines, as well as human embryonic kidney cell
line 293T (ATCC) were grown in Dulbecco’s Modified Eagle’s
Medium (Life Technologies) supplemented with 10% (v/v) heat-
inactivated fetal calf serum (FCS), 100 IU/ml penicillin and
100 mg/ml streptomycin (complete DMEM) at 37uC with 5%
CO2.
Molecular Cloning and Expression of CAIX Proteins and
Anti-CAIX Antibodies
Full length or different domains of CAIX cDNA were cloned
into mammalian or bacterial expression vector and expressed
alone, as human IgG-Fc or bacterial GST fusion proteins.
Likewise, anti-CAIX scFv antibodies were also subcloned and
expressed as soluble scFv format in bacteria or as scFv-Fc fusion in
mammalian cells. Details for subcloning and expression of the
recombinant proteins as well as establishing CAIX expressing
stable cell line are provided in Text S1.
Selection of Anti-CAIX Single-Chain Antibodies from
Nonimmune Human scFv Phage Display Library with
PMPL Panning
The antibody selection procedure including CAIX-PMPL pre-
paration and characterization, panning, cell-based ELISA screen-
ing, and confirmation by flow cytometric analysis as well as DNA
sequencing were basically performed following the procedure
described previously [38,39]. Additional details are provided in
Text S1.
Kinetic Analysis of Binding Interactions between
Anti-CAIX scFvFcs and CAIX-ECD-C9 by Surface
Plasmon Resonance (SPR)
The kinetic interactions between anti-CAIX scFvFcs and
CAIX-ECD-C9 were measured by SPR using Biacore T100.
Sensor chip CM4, amine coupling reagents [N-ethyl-N’-dimethy-
laminopropyl carbodimide, EDC; N-hydroxysuccinimide, NHS;
and 1 M ethanolamine HCl (pH 8.5)], human antibody capture
kit and HBS-EP+ buffer were obtained from GE Healthcare.
Specific procedure is described in the Text S1. Data analysis was
performed using Biacore T100 evaluation software (v1.1.1; GE
Healthcare). Data were double referenced by subtraction of
reference surface data and blank buffer sample data from all the
data sets. The affinity and rate constants of the antigen-antibody
interactions were determined by global analysis using a simple 1:1
langmuir binding model (A+B u AB), provided by the T100
evaluation software. However, the data sets of G6, G125 and G9
were analyzed using a 2-state model (A+B u AB u AB*) since
they indicate a more complex mechanism of interaction. Rmax
was set as a local parameter to account for the changing ligand
density due to the capture of fresh ligand in each binding cycle.
Epitope Mapping of Anti-CAIX scFvFc Antibodies
Biotinylation of CAIX-Fc fusion proteins and anti-CAIX
scFvFc antibodies. All fusion proteins and antibodies were
labeled with Pierce EZ-Link Sulfo-NHS-Biotinylation kit (Cat.
Novel CAIX Antibody Discovery
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biotinylated proteins were examined by SDS-PAGE and the
concentration determined by Micro BCA protein assay kit (Pierce).
ELISA with purified biotinylated CAIX-Fc fusion pro-
teins. 5 ug/ml of 14 different anti-CAIX scFvFc in PBS were
coated onto a 96 well maxi-sorp plate at 4uC overnight. An
irrelevant scFvFc antibody 1567 or PBS only was used as negative
controls. After blocking with 2%BSA/4%milk/PBS for one hour
at room temperature (RT) and washing with ELISA washing
buffer (0.05% Tween 20 in PBS, PBST) four times, equal molar
concentrations of biotinylated CAIX-ECD-Fc (6 mg/ml), CAIX-
CA-Fc (5 ug/ml) or CAIX-PG-Fc (3 mg/ml) in 1%BSA/PBS was
added and incubated for 1 hour at RT. Specific binding of
antigens was detected by incubation with HRP-labeled
streptavidin followed by addition of TMB substrate for color
development. OD450 values were determined by Bio-Rad
microplate spectrophotometer.
ELISA with CA-GST and PG-GST fusion proteins. 96-well
plate was coated with 50 ml PBS containing 5 mg/ml CA-GST or
PG-GST fusionproteinsat 4uC overnight. HA-GST, a fusion protein
between HA1 domain of hemagglutinin (HA) of A/Thailand/2(SP-
33)/2004 (H5N1)(GenebackAccession# AAS65618) and GST, was
cloned, purified and used as a negative control. Upon blocking with
200 ml 4% non-fat milk, 50 mlo f5mg/ml of anti-CAIX scFvFc
antibodies were added to each well and incubated for 1 hr at RT.
Irrelevantanti-CXCR4scFvFcantibodyX33orsamevolumeofPBS
was used as negative controls. Specific binding was detected with
50 ml HRP-labeled goat-anti-human Fc IgG and color development
was the same as described above.
Competition binding to CAIX-ECD-Fc protein. 96-well
plate was coated with 50 ml PBS containing 5 mg/ml CAIX-ECD-
Fc fusions proteins at 4uC overnight. After blocking with 200 ml4 %
non-fat milk, 50 mlo f5mg/ml of biotinylated anti-CAIX scFvFcs
were added to each well in the presence or absence of 250 ng of a
competing unlabeled antibody, and incubated for 1 hr at RT.
Human anti-CXCR4 scFvFcX33 or PBS was used as negative
controls. The plate was processed with 50 ml HRP labeled
streptavidin and color-developed with 100 ml TMB peroxidase
substrate sameas the procedure described above. The percentage of
binding was calculated using the formulation: %=100*(OD450 of
labeled scFvFc + unlabeled scFvFc)/(OD450 of labeled scFvFc +
PBS). Note that all ELISA samples were assayed in duplicates.
Inhibiting Carbonic Anhydrase Activity of Soluble
CAIX-ECD-Fc by Anti-CAIX scFvFc Antibodies
The procedure described online at http://www.worthington-
biochem.com/CA/default.html was followed for the carbonic
anhydraseactivityassay.Forblankdetermination:4 mlchilled CO2
saturated water was added to 6.0 ml chilled 0.02 M Tris HCl
buffer, pH 8.0 and the time (in seconds) required for the pH to drop
from 8.3 to 6.3 was recorded as T0.1mg of CAIX-ECD-Fc in
100 ml of PBS was added to 6.0 ml chilled 0.02 M Tris HCl buffer,
pH 8.0 immediately before adding of CO2 saturated water. The
time needed for pH drop was set as T. The Unit activity of carbonic
anhydrase was calculated according to the following formula:
Units/mg=2 6(T0-T)/(T6mg enzyme in reaction mixture). To
determinetheeffectsonCAIXactivity,the anti-CAIXscFvFcswere
mixed with 1 mg of CAIX-ECD-Fc at the molar ratio of Abs:
enzyme =1:1, 5:1 or 25:1 and then incubated at room temperature
for 50 minutes. The mixture and 4 ml CO2 saturated water were
added to 6.0 mlchilled 0.021 M Tris HClbuffer, pH 8.0ina 50 ml
Falcon tube, and the time required for the pH drop from 8.3 to 6.3
was recorded as TAb. The small molecular carbonic anhydrase
inhibitor, acetazolamide (ATZ, Sigma) and irrelevant scFvFcX33
were used as positive and negative controls, respectively. Units
activity of carbonic anhydrase inhibited by scFvFcs was calculated
according to the following formula: UnitsAb/mg=26(T02TAb)/
(TAb6mg enzyme in reaction mixture) and the percentage of
inhibition was calculated as: % of Inhibition =1006[12(UnitsAb/
mg)/(Units/mg)].
Antibody-Induced CAIX Internalization
General flow cytometry. 293T-CAIX or 293T cells were
incubated with individual anti-CAIX scFvFcs labeled with
CypHer5E according to the manufacturer’s instructions (GE
Healthcare). The change in CypHer5E fluorescence, which is pH
sensitive with minimal extra-cellular fluorescence in standard culture
mediaandmaximalintra-cellularfluorescenceinacidicintra-cellular
compartments such as the endosome, is used to monitor the effect of
antibodies on internalization of the surface-expressed CAIX.
293T-CAIX cells were incubated with serum free DMEM
medium for 4 hours and collected with 5 mM EDTA/PBS.
2.5610
6 cells were incubated with a saturating amount (2.5 mg)
of CypHer5-labelled anti-CAIX scFvFcs in a 100 mlo fP B C /
0.5%BSA at 37uC or on ice for 15, 30, 45 or 60 minutes. Irrelevant
scFvFc11A and scFvFcX48 as well as free CypHer5 dye were used
as negative controls. YO-PRO-1 nucleic acid staining (Invitrogen)
was used to monitor cell viability by incubating with cells for 20 min
on ice. Unbound antibodies and stains were removed by washing
thecellswithPBS/0.5%BSAforthree times.Cells wereanalyzed by
general flow cytometry using FACScalibur (BD).
Quantitative imaging flow cytometry with ImageStream
system (Amnis Corp, Seattle, WA) was used for colocalization
studies. Upon staining with CypHer5-labelled anti-CAIX scFvFcs
G37, G119, and G36, cells were washed, permeabilized and fixed
with 100 ml of Perm/Fix solution for 20 min at RT. Cells were
sequentially stained in 100 ml of Perm/Wash buffer containing
10 mg/ml FITC mouse anti-human EEA1 or PE-Cy5 mouse anti-
human CD107a (LAMP1) for 20 minutes on ice. The cells were
further washed twice with 1 ml of Perm/Wash buffer each, fixed
cells with 1% paraformaldehyde, adjusted to 5610
7/ml (2.5610
6/
50 ml) and transferred to 500 ml siliconized microcentrifuge
tubes for analysis by ImageSream system. 5,000–15,000 event
multispectral images were acquired for each sample on an
ImageStream imaging flow cytometer (Amnis Corp, Seattle, WA).
Single color control samples were used to create a compensation
matrix that was applied to all files to correct for spectral crosstalk,
and the resulting compensated image data was analyzed in the
IDEAS software program (Amnis). Single cell events with
intermediate area and high aspect ratio were gated to eliminate
debris (low area) and multi-cellular events (large area, low aspect
ratio) from further analysis. Bright punctate EEA1 or LAMP1
staining areas with a diameter of 3 microns or less were
automatically counted using the spot count feature for
EEA1+LAMP1 +CypHer+ and EEA1+LAMP1+CypHer- cells.
Results
Construction and Characterization of CAIX-PMPLs
Celllysates from stably transfected 293T-CAIX cellswereused to
prepare CAIX-containing paramagnetic proteoliposomes (CAIX-
PMPLs) [38,39]. CAIX-PMPLs were pelleted, treated under
reducing conditions, and the supernatant was subjected to SDS-
PAGE analysis and visualized by Coomassie Blue staining. As
shown in the left panel of Figure 1A, a circa 45 kDa mol wt band
corresponding to CAIX is seen only in Lane 1, which was captured
from cell lysate by the 1D4-coupled M280 beads. The two other
protein bands detected in Lanes 1 and 2 correspond to the 1D4
Novel CAIX Antibody Discovery
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proteins were present at only trace levels. CAIX-PMPL purity was
further checked by using cell lysates metabolically labeled with
35S-
methionine/cysteine. The right panel of Figure 1A represents an
autoradiogram that shows only one predominant band with the
expected mol. wt. of CAIX was observed in PMPLs constructed
with 293T-CAIX cell lysates (lane 1), while no band was detected
from PMPLs formed with parental 293T cell lysates (lane 2).
Isolation of CAIX-Specific Antibodies from a Phage
Display Library
Two non-immune human scFv-phage display libraries contain-
ing 12 (Mehta I) and 15 (Mehta II) billion members were
combined and used to directly isolate CAIX specific antibodies.
The panning and selection processes are illustrated in Figure 1B
and results summarized in Figure 1C. Sixteen out of 96 clones
from the first round and 109 out of 192 clones from the second
round of CAIX-PMPL panning specifically bound to 293T-CAIX
cells as detected by cell-based ELISA and confirmed by flow
cytometric analysis with phage antibodies (data not shown). DNA
sequence analysis revealed a total of fourteen unique scFv clones
(Table S1). There is a predominance of VH germline VH3-23
usage that has recombined with five different JH segments to form
the rearranged heavy chain genes. Likewise, the Vl germline V1-
40 gene was predominantly used in combination with Jl2-3
segments. A phylogenetic tree based on translational alignment of
nucleotide sequence comparison [40] of these fourteen antibodies
is presented in Figure 1D.
Cell Surface Binding of Anti-CAIX scFvFcs Measured by
Flow Cytometry
All fourteen anti-CAIX scFvs were subcloned, expressed in
293FT cells, and purified as scFvFc fusion proteins (Figure 2A).
The binding activities of these bivalent proteins were further
examined by flow cytometric analysis. The results demonstrated
that 13 anti-CAIX scFvFcs could recognize the CAIX positive
human renal clear cell carcinoma (RCC) sk-rc-52 cells, but not the
CAIX negative RCC sk-rc-59 cells. G104 scFvFc bound to both
cells, therefore, its binding was considered non-specific (Figure 2B).
The relative affinity of each anti-CAIX scFvFc to native CAIX
molecules was determined by staining of the 293T-CAIX cells
using serial dilutions of each scFvFc in flow cytometric saturation
binding studies (Figure 2 C&D). The concentration of antibody to
reach 50% of maximum percentage positive staining cells and
respective geometric mean fluorescence intensity (GMFImax) are
shown in Table 1. All scFvFcs reached ,100% positive binding at
relatively low concentrations compared to that needed to obtain
GMFI saturation. The EC50 values for reaching 50% positive
binding ranged from 0.05 nM for G106 to 24.8 nM for G9.
Similarly, the EC50s for the half-maximal GMFI also showed a
broad range from 1.2 nM for G45 to 310.5 nM for G9 (Figure 2C
and 2D, Table 1). However, in contrast to the attainment of near
complete ($98%) saturable binding reached by all the antibodies,
the plateaus reached by the different antibodies were not the same.
Antibodies G10, G36, G37, G39, G45, G57, G106 and G119,
reach a higher plateau (GMFI max between 352 and 476) than
G6, G27, G40 and G125 that fall in an intermediate group (GMFI
max between 239 and 284). In the case of G9, the antibody did not
reach a plateau of GMFI at the highest concentration tested
(100 mg/ml).
Kinetic Analysis of Anti-CAIX scFvFc Binding by Surface
Plasmon Resonance (SPR)
The binding characteristics of each anti-CAIX scFvFc were
further analyzed by SPR through a capture technique, where
purified anti-CAIX scFvFc was captured onto a BiaCore CM4
Figure 1. Characterization of CAIX paramagnetic proteoliposomes (CAIX-PMPLs). A (left),3 610
7 CAIX-PMPLs (lane 1) or M280 Dynal beads
coated with 1D4 mAb only (lane 2) were treated with 2xSDS-buffer for 1 hr at 55uC followed by boiling for 5 min. The supernatant were used for SDS-
PAGE analysis and proteins were visualized by Coomassie Blue staining. A (right), PMPLs were incubated with [
35S]-methionine/cysteine labeled 293T-
CAIX-C9 (lane 1) or 293T (lane 2) cell lysates. Purity of the PMPLs was determined by SDS-PAGE followed by autoradiography analysis. B. Schema of
the antibody panning and selection process. C. Summary of CAIX-PMPL panning results. D. Phylogenetic tree of the fourteen (14) unique anti-CA IX
antibodies based on translational alignment of nucleotide sequence comparison using Geneious (http://www.geneious.com/) software with PHYML
tree plugin (http://atgc.lirmm.fr/phyml). Jukes-Cantor genetic distance model were utilized. Consensus tree option was selected with 100 bootstraps.
The unit of measure (the scale bar) represents the number of amino acid substitutions per site.
doi:10.1371/journal.pone.0009625.g001
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PLoS ONE | www.plosone.org 4 March 2010 | Volume 5 | Issue 3 | e9625Figure 2. Characterization of selected anti-CAIX scFvFc antibodies. A. Different anti-CAIX scFvFcs were expressed and purified from 293FT
cells as discussed in Material and Methods. A total of 2 mg purified each anti-CAIX scFvFc were treated with 5XSDS-PAGE loading buffer (Pierce) in the
presence (lower panel) and absence (upper panel) of reducing reagent DTT. The antibodies were separated by SDS- 10% Tris-Glycine PAGE gel
electrophoresis and visualized by Coomassie Blue staining. B. Flow cytometric analysis of the anti-CAIX scFvFc binding activity. One microgram (1 mg)
of each anti-CAIX scFvFc was incubated with 5610
5 sk-rc-52 (CAIX positive) or sk-rc-59 (CAIX negative) cells in 50 ml FACS buffer (1% BSA/PBS),
followed by staining with PE-conjugated goat anti-human IgG. Binding activity of each antibody was examined by flow cytometric analysis and data
is presented as overlapping histograms of the CAIX positive and negative cells as well as the secondary antibody only controls for each cell line.
Similar findings were found in two independent experiments. C&D . Dosage-dependent binding of the anti-CAIX scFvFcs to 293T-CAIX cells. Anti-
CAIX scFvFcs or a control of irrelevant anti-CXCR4 scFvFc (X33) at the concentrations indicated on the X-axis were incubated with 5610
5 293T-CAIX
cells followed by staining with FITC conjugated goat anti-human IgG. Flow cytometric analysis was performed and binding activity of each antibody
is presented as both percentage of positive cells (C) and absolute geometric mean fluorescence intensity (GMFI) (D). A summary of the calculated
EC50 for half-maximal percent binding (C) and GMFI (D), along with maximal percent positive cells and GMFI reached, are presented in Table 1.
doi:10.1371/journal.pone.0009625.g002
Table 1. Anti-CAIX antibody affinity as analyzed by flow cytometry and SPR.
scFvFc Ab KD (nM) Maximum GMFI EC50 (nM) GMFImax EC50 (nM) Bindingmax
G119 1.49 415.23 2.9 0.18
G10 1.62 367.8 2.9 0.21
G37 1.89 401.8 3.9 0.22
G106 3.20 359.54 3.4 0.05
G36 3.22 376.15 2.6 0.17
G39 3.43 476.23 5.1 0.20
G57 4.25 422.61 17.6 0.92
G45 12.50 351.5 1.2 0.11
G40 21.78 275.47 2.6 0.21
G27 25.12 283.94 30.3 1.10
G6 25.90 238.54 33.3 0.80
G125 40.32 252.1 6.4 0.87
G9 99.58 160.53 310.5 24.78
Correlation between SPR
KD & Flow cytometry
Rcalculated 20.849 (p,0.01) 0.908 (p,0.01) 0.904 (p,0.01)
The EC50 values represent the concentrations of scFvFcs required to reach half-maximal geometric mean fluorescence intensity (MGFI) or circa 50% positive cell staining
by flow cytometric analysis, respectively. KD values determined by SPR were taken from Tables 2 and 3.
doi:10.1371/journal.pone.0009625.t001
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carboxy-terminal C9-tagged extracellular domain of CAIX
(CAIX-ECD, amino acids 1-391) purified from 293FT cell culture
supernatant was used as the antigen analyte. The fitted kinetic
sensorgrams are shown in Figure S1. Non-specific binding to the
reference anti-human Fc surface was not observed. The anti-
CAIX scFvFcs were ranked based on their affinity (KD value) to
CAIX-ECD-C9 (Tables 2 and 3). Note that the eight highest
affinity antibodies were also the eight antibodies that displayed the
higher GMFImax plateau in Figure 2D (KD#12.50 nM) while the
five lower affinity antibodies (KD$21 nM) reached only the
intermediate GMFI max plateau or for G9 never reached the
plateau (also refers to Table 1). There is significant correlation
between the EC50 for GMFI or maximal percentage of binding
and KD as determined by BiaCore (Table 1).
Epitope Mapping Studies with CAIX Fusion Proteins
Purified CAIX-ECD-Fc, carbonic anhydrase domain (CA-Fc)
and proteoglycan domain (PG-Fc) fusion proteins (Figure 3A–C)
were used to map the CAIX epitopes recognized by the anti-
CAIX antibodies in ELISA assays. Plates were coated with
purified anti-CAIX or an irrelevant scFvFc antibody 1567 and
incubated with equal molar concentrations of biotinylated CAIX-
ECD-Fc, CAIX-CA-Fc or CAIX-PA-Fc. The data in Figure 3D
indicates that all antibodies recognized the CA domain while none
of the antibodies recognized the CAIX PG domain.
When reacted with CA-GST, PG-GST, or HA-GST (control)
fusion proteins expressed and purified from bacteria (Figure 3B-C
and data not shown), anti-CAIX scFvFc antibodies again did not
recognize the CAIX PG domain coated on the plate (Figure 3E).
The G10, G36, G37 and G106 had significant binding to the CA-
GST (OD450 .2) while G6, G9, and G39 reacted with the CA-
GST weakly. In contrast to the results in Figure 3D, G27, G40,
G45, G57, G119 and G125 did not recognize the bacterially
produced CAIX-CA-GST, suggesting that binding of these
antibodies to the CA domain may be dependent upon unique
protein folding of the CA domain and/or post-translational
modification that are only present when produced in mammalian
cells. The fact that CAIX has been shown recently to contain an
intramolecular disulfide bridge, both N-a n dO-linked glycosyla-
tion [14], as well as tyrosine phosphorylation [41] supports our
hypothesis. It should be noted that in addition to above
biochemically characterized post-translational modifications, the
NetPhos 2.0 Server software [42] (http://www.cbs.dtu.dk/services/)
also predicts additional phosphorylation sites at tyrosine 289,
threonine 333, and serine residues at 153, 162, 201, 237 and 287
sites with high confidence,along with threonine 205 predicted bythe
NetOGlyc 3.1 Server as a potential O-linked glycosylation site, all
within the CAIX CA domain.
To understand further the nature of anti-CAIX scFvFcs binding
within the CA domain, antibody cross-competition studies were
performed. Specifically, purified anti-CAIX scFvFc proteins were
biotinylatedand flowcytometriccompetitive bindingassayswereset
up to determine whether presence of an unlabeled anti-CAIX
scFvFc could block the binding of any biotinylated scFvFcs to
the CAIX expressed on cell surface, the latter detected using
streptavidin-FITC. Diminished or reduced binding of the biotiny-
lated scFvFc in the presence of non-labeled blocking antibody could
indicate that antibodies have the same or overlapping binding sites
(epitopes) or the existence of steric hindrance. Table S2 summarizes
the results from this series of experiments. Antibodies are grouped
based primarily on their amino acid sequence homology (repre-
sented by the same color shade of the antibody names) with the
highest affinity mAb G119 at the top left and descending affinities
eitherdownthecolumnsormoving totherightalongeachrow.The
‘‘+’’ and ‘‘-’’ signs in Table S2 represent the percentage of
biotinylated antibody binding remaining. In general, the highest
affinity antibodies, as expected, show the greatest breadth of cross-
competition. It appears that G119, G10, G37, G106, G36, G45,
G39, G57, G40 and G6 share similar characteristics in that they
bind to the same or overlapping epitopes in the CA region as they
are capable of blocking or interfering all other antibodies binding to
the CAIX ECD domain and the degree of blocking correlates
strongly with their binding affinities (KD). Although the binding
affinity of G27, G125, and G9 ranked the lowest among all the anti-
CAIX antibodies selected (Tables 2 and 3), their binding could not
be blocked completely by any other antibodies. The data indicate
Table 2. Kinetic and equilibrium dissociation constants for
anti-CAIX scFv-Fc/CAIX-ECD-C9 interactions.
scFvFc Ab KD (nM)
ka (M
21s
21)
(610
5)
kd(s
21)
(610
23)
G119 1.4960.30 5.8061.29 0.8460.04
G10 1.6260.50 5.5061.46 0.8460.02
G37 1.8960.51 3.9261.23 0.7060.06
G106 3.2060.72 4.7261.58 1.4460.14
G36 3.2260.66 5.1063.15 1.5460.67
G39 3.4360.19 4.6460.06 1.5960.11
G57 4.2560.06 3.3760.06 1.4360.01
G45 12.5060.07 6.1760.37 7.7060.04
G40 21.7864.41 3.5261.49 7.3561.69
G27 25.1263.62 2.2460.43 5.5460.27
The kinetic constants of all CAIX antibodies except G6, G125 and G9 were
obtained by global analysis using a 1:1 langmuir binding model (A+B '
Ka
Kb
AB)
using the T100 evaluation software. The values are the average of 2-3 different
experiments.
doi:10.1371/journal.pone.0009625.t002
Table 3. Kinetic and equilibrium dissociation constants for interactions of CAIX-ECD-C9 with scFv-Fc G6, G125, and G9 antibodies.
scFv-Fc Ab KD (nM) ka1 (M
21s
21)( 610
5) kd1 (s
21)( 610
21) ka2 (s
21)( 610
22) kd2 (s
21)( 610
23)
G6 25.9062.38 3.7560.27 2.0260.03 1.1160.01 0.5660.05
G125 40.32615.60 3.5860.98 0.4260.04 0.3960.07 1.9160.43
G9 99.58623.36 2.2460.49 2.3760.90 1.6360.06 1.7160.07
When analyzed with the T100 evaluation software, G6, G125 and G9 curves indicate a more complex mechanism that will require further examination. However, for the
purposes of the present study of comparative affinity and ranking of the antibodies, the data sets of G6, G125 and G9 were fitted to a 2-state model, A+B '
Ka1
Kd1
AB '
Ka2
Kd2
AB*
and shown separately. The values are the average of 2–3 different experiments.
doi:10.1371/journal.pone.0009625.t003
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may recognize same binding site based on their blocking patterns,
G27 and G125 do not necessarily share the same epitope. This is
evidenced by the fact that they do not block each other’s binding
and exhibit differentblocking patterns to otherantibodies.Finally, it
should be noted that G119 only exhibited 20–40% self-blocking.
We believe this was most likely a result of the experimental
procedure employed since the cross-competition assay was
performed in a mixture of biotin-labeled and unlabeled antibody
at 1:1 ratio in the absence of preincubation of CAIX-coated plates
with unlabeled antibodies in excess. Under these conditions and
considering the high affinity (slow off rate) of G119, it is not
surprising to detect biotin-labeled G119 binding to CAIX even in
the presence of unlabeled G119.
Inhibition of Carbonic Anhydrase Activity by Anti-CAIX
Antibodies
Carbonic anhydrases (CA) catalyze the reaction: CO2 + H2O
« H2CO3. Since the anti-CAIX antibodies are epitope mapped
to the CA domain, their abilities to block the carbonic anhydrase
Figure 3. Binding specificity of the anti-CAIX antibodies as analyzed by domain mapping studies. A. Amino acid sequence of CAIX with
amino acid locations of the different segment/domains as indicated. B. Diagram of CAIX functional domains and fusion constructs. C. Coomassie Blue
staining of 2 mg purified CAIX-ECD-Fc (lane 1 & 4), CAIX-CA-Fc (lane 2 & 5), and CAIX-PG-Fc (lane 3 & 6) separated by SDS-PAGE under non-reducing
(lanes 1-3) or reducing (lanes 4-6) conditions. D. Binding of purified biotinylated CAIX-Fc constructs to the purified anti-CAIX scFvFcs analyzed by
ELISA. E. Binding of purified anti-CAIX scFvFcs to the CAIX–GST fusion proteins analyzed by ELISA. For D and E, average OD450 of each duplicated
sample is presented. Similar results were obtained in two independent experiments. Details on the ELISA assays performed are provided in
Experimental Procedures.
doi:10.1371/journal.pone.0009625.g003
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and compared with svFvFcX33 negative control, G6, G37, G39
and G125 scFvFcs showed different degrees of inhibition on the
CAIX-CA-Fc enzymatic activity (Figure 4A). Their inhibitory
activities appear to be specific in a dose-sensative manner
(Figure 4B). The monovalent scFv form of the G6 and G125 are
as effective, if not more, in blocking carbonic anhydrase activity
than their bivalent scFvFc counterparts (Figure 4C), presumably
resulted from easier access of the catalytic site by a smaller
antibody molecule.
Flow Cytometric and Imaging Studies of Antibody
Induced CAIX Internalization
For the initial screening, 293T-CAIX or 293T cells were incubated
with saturating amounts of CypHer5E labeled-anti-CAIX scFvFcs at
4uCo r3 7 uC for 60 minutes and antibodies with appreciable amounts
of CypHer5E fluorescence, an indication for internalization, were
chosen for further time-course study (data not shown). As shown in
Figures 5A and 5B, as compared with the negative control antibodies
11A and X48, G10, G27, G36, G45, G106, and G119 were found to
induce CAIX internalization only in 293T-CAIX cells. This result
was also confirmed with internalization studies using CAIX positive
RCC cells sk-rc-52 at 37uCo ro ni c e( F i g u r e5 C ) .
To determine the intracellular trafficking pattern of the
internalized antibody-CAIX complexes, anti-CAIX scFvFc G36
and G119 were selected for co-localization studies of CypHer5E-
labeled anti-CAIX antibodies to endosomes (stained with FITC
anti-EEA1) or lysosomes (stained with PE anti-LAMP1) using
quantitative imaging flow cytometry (Figure 6). Antibody G37 that
did not induce CAIX internalization as analyzed by regular flow
cytometry (data not shown) was used as a negative control.
Figure 6A shows that once again, compared to the cells stained
with G37 (0.9%), a significant percentage of 293T-CAIX cells
incubated with G36 (16.8%) and G119 (19.2%) were CypHer5E
positive. Representative cell images from CypHer5E positive and
negative populations are also shown in Figure 6A. Although co-
localization of CypHer5E staining with endosomal EEA1 or
lysosomal LAMP1 markers were not visually observed within
CypHer5E+ cells incubated with scFvFc G36, 119, or 37, a
significant decrease in number of EEA1 spots in CypHer5E+ but
not CypHer5E- cells was noted. This loss in EEA1 texture in
CypHer5E positive cells was quantified and confirmed using the
spot count feature of the IDEAS image analysis software by
Amnis, which automatically counts bright punctate staining
areas less than 3 microns in diameter. As shown in Figure 6B,
percentage of cells containing more than 5 EEA+ spots was greatly
reduced among CyeHer5E+ compared to the CyeHer5E- cells
while no significant differences were observed regarding the
LAMP1 spot count; indicating that internalization of antibody and
CAIX complexes into endosomes may have caused quenching of
the EEA-FITC signal.
Discussion
Epitopes expressed on the cell surface of tumor cells are superior
targets for anti-cancer immune therapy since, unlike intracellular
antigens; they are accessible to circulating antibodies in vivo. In the
last few years, human monoclonal antibodies (mAbs) have become
a well-tolerated and preferred treatment option for an increasing
Figure 4. Inhibition of carbonic anhydrase activity of CAIX by the anti-CAIX scFvFc antibodies. The ability of the anti-CAIX scFvFc
antibodies to inhibit the reaction CO2+H2O R H2CO3 catalyzed by CAIX (CAIX) was assessed using the electrometric assay as described in
Experimental Procedures. Different molar ratio of antibody to CAIX enzyme was tested. The anti-CXCR4 scFvFc X33 and carbonic anhydrase inhibitor
acetazolamide (AZT) were used as negative and positive control, respectively. Percent inhibition of CAIX enzymatic activity was calculated per
formula discussed in the Experimental Procedures. A. Inhibition of CAIX enzymatic activity by anti-CAIX-scFvFc at molar ratio 25:1. B. Inhibition of
CAIX enzymatic activity by selected anti-CAIX-scFvFc at molar ratio 1:1, 5:1, and 25:1. C. Inhibition of CAIX enzymatic activity by selected anti-CAIX-
scFv antibodies at molar ratio 1:1, 5:1, and 25:1. Values represent an average of three different experiments.
doi:10.1371/journal.pone.0009625.g004
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mouse-antibody) or HACA (human anti-chimeric-antibody) re-
sponses when used in clinical applications. As accumulating
evidence indicates that CAIX is a very promising target for tumor
immune therapy and diagnosis, there is a great need for discovery
of additional anti-CAIX antibodies, especially antibodies of
human origin, to fulfill the need for various clinical applications.
In this study, using PMPL incorporated with CAIX in its native
conformation, we selected and characterized 14 human antibodies
from a large human scFv antibody library. The antibodies with
diverse functions were isolated very early during the selection
(Figure 1C), again demonstrating that PMPL is a powerful tool for
isolation of human antibodies against self-antigens when used in
combination with the large naı ¨ve human scFv phage display
library [38,39]. Sequence analysis indicates that most of the
antibodies belong to the VH3-23 of H chain (13 Abs) and V1-40 of
l light chain (12 Abs) families. Other germlines represented
include VH3-30 for G27 and Vl3-21 for G27 and G125. As
expected, significant sequence diversity resides within the CDR,
especially CDR3 of both H and L chains. Thirteen antibodies
interact with overlapping or different epitopes within the CA
domain and seven with measured affinity binding constant (KD)
between 1.5 nM to 4.3 nM. At least four antibodies are capable of
inhibiting the CA activity and six induce surface CAIX
internalization efficiently (see Table 4 for summary).
To date, antibodies against human CAIX molecules have been
generated by traditional hybridoma technology through fusion of
myeloma cells with the splenocytes from mice immunized with
primary RCC lesions [16], Hela cells [13], and more recently from
CAIX-deficient mice immunized with NIH3T3-CAIX cells with
or without purified GST-CA protein boosts [37]. The generated
CAIX antibodies primarily reacted with the PG domain unless the
immunization scheme contained a boost injection of purified
recombinant CA domain, presumably due to immunodominance
of the N-terminal located and highly acidic PG domain [43].
Armed with CAIX-PMPL and phage display technology, the
human anti-CAIX antibodies isolated in vitro avoided immunu-
dominance of the PG domain and all recognized epitopes in CA
region. Based on cross competition studies, these antibodies may
recognize $3 different epitopes. In addition, four antibodies G6,
G37, G39, and G125, clearly demonstrated their abilities of
inhibiting carbonic anhydrase activity of the CAIX-PMPL, a novel
biological activity that has not been previously described for CAIX
antibodies. Since the enzymatic activity is believed to contribute to
CAIX ability to promote tumor growth/survival [22,23] and a
carbonic anhydrase inhibitor has been reported to suppress
invasion of renal cancer cells in vitro [44], the newly discovered
CA-inhibitory antibodies can be tested for their anti-RCC activity
in vivo, which could provide a different mechanism for RCC
immune therapy.
Six CAIX antibodies discovered exhibited different degrees of
abilities to induce internalization of surface-expressed CAIX as
judged by pH sensitive CypHer 5E labeled antibodies using flow
cytometry (Figure 5). In addition, G119 and G36 induced CAIX
internalization to endosomes was confirmed by imaging (Figure 6).
These antibodies could be conjugated with a toxin to achieve
targeted tumor killing or fused with a nucleic acid-binding moiety
for target therapeutic gene delivery [45,46]. On a separate front,
antibodies specific to tumor surface markers, based on its
internalization function, could be used for molecular imaging
with different radioisotope labels and aid in diagnostic of tumor
type and choice of treatment plans [35]. It should be pointed out
that antibodies G45, G119, G10, G37, G36, and G106, although
belong to the same cluster in the genetic tree and have identical
CDRs in their VH regions (Figure 1D and Table S1), do not
necessarily possess same characteristics. For example, compared
with the other 5 antibodies in this group, G45 has a low affinity
constant (KD=12.5 nM) and is not able to inhibit CA activity or
bind to bacterially produced CA-GST fusion protein. G37, while
having similar properties in most criteria as other Abs in this
group, failed to induce CAIX internalization (Figure 6 and
Figure 5. Induction of CAIX internalization from cell surface by
anti-CAIX antibodies. CypHer5E-labeled anti-CAIX scFvFc antibodies
were tested for their abilities to induce CAIX internalization by flow
cytometric analysis. The 293T cells (A) or 293T-CAIX cells (B) were
incubated at 37uC with 2.5 mg/100 ml CypHer5E-labeled anti-CAIX
scFvFc antibodies for 15, 30, 45, or 60 minutes. Two irrelevant scFvFc
antibodies, 11A and X48, as well as CypHer5E dye were used as
negative controls. C represents a similar experiment where CAIX
internalization in sk-rc-52 (CAIX positive) cells were analyzed and
compared at 37uC and 0uC. Fluorescence intensity of cells was analyzed
using FACS Calibur and GMFI value (A & B) or percent of CypHer5E
positive cells (C) were presented in corresponding panels.
doi:10.1371/journal.pone.0009625.g005
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changes in VL CDRs are the likely contributing factors for the
functional difference. This is especially notable in the case of G36
and G37, where the only significant difference is a R to S change
in VL CDR3 (Table S1), yet G36 internalizes whereas G37 does
not. To our knowledge, this unique property of antibodies has not
been previously reported. Additional studies on specific residues in
VL CDRs, especially X-ray crystallographic and/or mutational
studies, could further our understanding of the CAIX structural/
function relationship, the critical contact residues of the antibody,
as well as rational design of a better therapeutic anti-CAIX
antibody.
Many mechanisms have been proposed for the ability of
antibodies to mediate their anti-tumor effects in vivo. For example,
engagement of the antibody Fc domain with effecter cell FccRs
leads to antibody-dependent cell-mediated cytotoxicity (ADCC).
Some (antagonist or inhibitory) antibodies can block the signaling
on tumor cells and in this way may act synergistically with immune
effector responses by rendering the tumor cells more susceptible to
immune effecter cell triggered apoptosis or lytic cell death [47].
Another way that antibodies can be utilized is through the
construction and functional expression of chimeric-immune
receptors or ‘‘T-bodies’’ on T-lymphocytes otherwise known as
‘‘designer T-cells’’ [48,49]. T-lymphocytes grafted with a chimeric
receptor have the combined advantages of MHC-independence
and antibody-based antigen binding with efficient T-cell activation
upon specific binding to the receptor ligand. On the other hand,
single-chain antibody-based bispecific T cell engagers (BiTE),
which are capable of engaging cytotoxic T cells for lysis of tumor
cells, have recently been shown to have therapeutic potential for
treatment of non-Hodgkin’s lymphoma in a clinical setting [50]. It
worth noting that as CAIX expression, which is trans-activated by
hypoxia inducible factor-1a [51], has been reported in increasing
cases of other cancers, such as lung, cervical, ovarian, esophageal,
breast, prostate, bladder, and head and neck squamous cell
carcinomas [52–54], the human CAIX antibodies discovered in
this study will become very valuable reagents and be evaluated for
their ability against different types of cancer through not only each
above-mentioned mechanism but also their newly discovered
carbonic anhydrase inhibitory effects.
Supporting Information
Figure S1 Characterization of anti-G250 scFv-Fcs based on
their kinetic interactions with the antigen, G250-ECD-C9. The
antibody/antigen interactions were studied by SPR via a capture
technique, with anti-human Fc as ligand and purified CA IX-
ECD-C9 as analylyate using Biacore T100. Sensograms shown are
double referenced (reference surface and blank-buffer subtracted).
Five different concentrations of the analyte diluted serially from
50, 100 or 400 nM were used for different antibodies (50 nM-
G119, G10, G37; 100 nM- G106, G36, G39, G57, G45, G40,
G27; 400 nM- G6, G125, G9). The kinetic constants were
obtained by global analysis using a 1:1 Langmuir binding model
(shown in black) using the T100 Evaluation software for
comparative analysis of the antibodies. G6, G125 and G9 showed
better fitting to a two-state model. The kinetic constants shown in
Table 3 were the average of 2–3 assays.
Figure 6. Antibody-induced CAIX internalization as analyzed by ImageStream. A. Single cells expressing EEA1 and Lamp1 were gated (R2),
and the CypHer5E intensity was plotted for cells incubated with anti-CAIX G37, 119, or 36 (left, center, and right plots), with the relative percentageo f
CypHer5E+ events (R3) displayed in the upper right of each plot. Representative Brightfield, EEA1 (green), LAMP1 (orange), and CypHer5E (red) cell
images from the three antibody treatment groups are shown below in the same order. B. The number of EEA1 or LAMP1 small punctate staining
regions is plotted for CypHer5E+ (R3) or CypHer5E- cells from the indicated antibody treatment groups. The percentage of cells with greater than four
spots (R4) is displayed in the upper right corner of each plot. Representative EEA1 images from the AbG36 sample of cells with zero (left), ten (center),
or twenty EEA1 spots (right) are shown below the plots.
doi:10.1371/journal.pone.0009625.g006
Table 4. Summary on properties of the newly discovered human anti-CAIX antibodies.
CAIX Abs
Affinity (KD)
(nM)
Mapping* (CA-GST)
(OD450)
Cross-competition
Grouping
% CA Inhibition by
anti-CAIX scFvFc Internalization
G119 1.49 2 12 5+++***
G10 1.62 3 1 15 +
G37 1.89 3 1 40** 2***
G106 3.20 2.4 1 20 ++
G36 3.22 3 1 10 ++***
G45 12.50 2 1 2 +
G39 3.43 0.25 1 50** 2
G57 4.25 2 1 22
G40 21.78 2 1a 15 2
G6 25.90 0.9 1a 50** 2
G27 25.12 2 2 2 +
G125 40.32 2 3 40** 2
G9 99.58 0.4 3 22
*All anti-CAIX antibodies recognize the CA domain but only a selected group interacts with bacterially produced CA-GST (Figure 3D &E).
**Percentage of carbonic anhydrase inhibition by CAIX antibodies was estimated from Figure 4B. The rest data are from Figure 4A.
***Internalization measured by both flow cytometry and ImageStream. + and 2 denotes degree of internalization as measured by regular flow cytometry (Figure 5).
doi:10.1371/journal.pone.0009625.t004
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PDF)
Table S1 Sequence analysis of CAIX-specific antibodies includ-
ing V and J germline gene usage.
Found at: doi:10.1371/journal.pone.0009625.s002 (0.08 MB
PDF)
Table S2 Binding site analysis through cross-competition studies
with different anti-CAIX antibodies.
Found at: doi:10.1371/journal.pone.0009625.s003 (0.66 MB
PDF)
Text S1 Supplemental Materials and Methods.
Found at: doi:10.1371/journal.pone.0009625.s004 (0.05 MB
DOC)
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